BAJAJ BROKING
Sun Pharma is set to acquire Checkpoint Therapeutics for up to $355 million. The deal includes an upfront payment of $4.10 per share, a 66% premium to Checkpoint’s last closing price. The acquisition strengthens Sun Pharma’s oncology segment, adding FDA-approved Unloxcyt to its portfolio.
Mumbai-based Sun Pharmaceutical Industries has finalised an agreement to acquire Checkpoint Therapeutics Inc. for up to $355 million (₹3,088 crore). This marks Sun Pharma’s second significant acquisition in two years, following its $576 million takeover of Concert Pharmaceuticals in 2023. The transaction is expected to close in the second quarter of 2025, pending regulatory approvals.
Also Read: Bharat Electronics Secures ₹843 Crore in New Defence Orders
Deal value: Sun Pharma will pay up to $355 million for Checkpoint Therapeutics.
Upfront payment: Shareholders will receive $4.10 per share, a 66% premium to Checkpoint’s closing price on 7 March 2025.
Contingent value rights: Additional payments of up to $0.70 per share depend on European regulatory approvals.
Strategic expansion: Sun Pharma strengthens its oncology portfolio, integrating Checkpoint’s FDA-approved Unloxcyt (cosibelimab-ipdl).
Financial performance: Checkpoint reported a $27.3 million net loss for the nine-month period ending September 2024.
Also Read: Aditya Birla Capital Infuses ₹300 Crore into Housing Finance Subsidiary via Rights Issue
Sun Pharma will acquire all outstanding shares of Checkpoint Therapeutics. Shareholders will receive $4.10 per share in cash, and an additional $0.70 per share if cosibelimab secures approval in key European markets.
Checkpoint Therapeutics, a Nasdaq-listed firm, is a commercial-stage immunotherapy company. Its lead product, Unloxcyt, is FDA-approved for cutaneous squamous cell carcinoma (cSCC). Despite this approval, Checkpoint faced financial struggles, with $0.04 million revenue and a $27.3 million net loss in the nine-month period ending September 2024.
Metric | Value (as of September 2024) |
Revenue | $0.04 million |
Net loss | $27.3 million |
Research and development expense | $19.3 million |
Cash balance | $4.7 million |
Accounts payable and accrued expenses | $15.6 million |
Checkpoint’s controlling stockholder, Fortress Biotech, has agreed to vote in favour of the acquisition. Fortress will also receive royalty payments from cosibelimab’s future sales.
The acquisition bolsters Sun Pharma’s presence in the oncology segment, reinforcing its strategy of expanding innovative treatments. Unloxcyt’s integration into Sun Pharma’s global portfolio is expected to strengthen its market positioning in the US, Europe, and other key regions.
Checkpoint’s board of directors formed a special committee to evaluate strategic options. After assessing multiple offers, the committee approved Sun Pharma’s proposal as the best risk-adjusted value for stockholders.
With this acquisition, Sun Pharma continues its global expansion in oncology-focused treatments. By adding Checkpoint’s FDA-approved Unloxcyt, Sun Pharma is expected to enhance its oncology business and further increase Sun Pharma share price. The acquisition, if successful, will contribute to Sun Pharma’s revenue while strengthening its oncology research capabilities. Investors will now monitor Sun Pharma share price closely as the deal progresses through regulatory approvals.
Also read: Syngene International to Invest $56 Million in US Subsidiary Expansion
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading